East Asia Pharmaceutical (605177.SH) released its first quarter results, with a net loss attributable to shareholders of 6.91 million yuan, turning from profit to loss.

China Finance App News, DongYa Pharmaceutical (605177.SH) released its first quarter report for 2025, with a operating income of 191 million yuan, a year-on-year decrease of 45.85%; a net loss attributable to shareholders of the listed company of 6.9196 million yuan, turning from profit to loss; a net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses of 10.5059 million yuan, turning from profit to loss; basic earnings per share was a loss of 0.06 yuan per share.